Agios to Unveil New Phase 3 Mitapivat Data at EHA 2026, Bolstering Efficacy in Rare Anemias
summarizeSummary
Agios Pharmaceuticals announced it will present new, previously undisclosed data on its lead drug candidate, mitapivat, at the European Hematology Association (EHA) Congress in June 2026. This includes detailed efficacy and safety data from the Phase 3 RISE UP trial in sickle cell disease, long-term data from the Phase 3 ENERGIZE trial in thalassemia, and Phase 2 data in other rare hemolytic anemias. The selection of the RISE UP trial for a distinguished plenary session underscores the significance of the findings, which include additional analyses of clinical benefit and patient-reported outcomes not previously disclosed. This positive update reinforces mitapivat's therapeutic potential and strengthens its commercial outlook across multiple rare hemolytic anemias, which could positively impact investor sentiment. Traders will be watching for the full data presentation at EHA 2026 in June for further insights into the drug's regulatory path and market adoption.
At the time of this announcement, AGIO was trading at $27.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $22.24 to $46.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.